MacroGenics, Inc.
 (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license agreement to develop a preclinical bispecific molecule with 

Janssen Biotech, Inc.
 The research collaboration will incorporate 

MacroGenics’
 proprietary DART® platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.

“We are excited to collaborate with Janssen, which we believe is a leader in the field of next generation antibody-based therapeutics, by bringing together our two companies’ respective scientific talent and experience to leverage our DART platform to generate a compelling product candidate that addresses unmet patient needs,” said  Scott Koenig , M.D., Ph.D., President and Chief Executive Officer of 

MacroGenics
.

Under the terms of the agreement, Janssen will pay 

MacroGenics
 an upfront payment of 

$20 million
 and will be responsible for funding all expenses. 

MacroGenics
 will also be eligible to receive up to 

$312 million
 in potential milestone payments and tiered royalties on worldwide product sales. Further details about the transaction are not disclosed.

Read the full article at: ir.macrogenics.com

The following two tabs change content below.
Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.